• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Lack of Persistence of Influenza Vaccine Antibody Titers in Patients with Heart Failure

tetano

Editor, Senior Moderator
J Card Fail. 2013 Dec 18. pii: S1071-9164(13)01280-3. doi: 10.1016/j.cardfail.2013.12.008. [Epub ahead of print]
Lack of Persistence of Influenza Vaccine Antibody Titers in Patients with Heart Failure.
Albrecht CM1, Sweitzer NK2, Johnson MR2, Vardeny O3.
Author information
Abstract
BACKGROUND:

Patients with heart failure (HF) have lower initial antibody responses to the influenza vaccine compared to healthy individuals. Whether antibody titers wane faster in this population remains unknown.
METHODS AND RESULTS:

We studied 62 HF patients (18 ischemic, 44 idiopathic) and 40 healthy controls (HC) during the 2006/2007 and 2007/2008 influenza seasons. Antibody titers were measured before, and 2-4 weeks, and 11-12 months after vaccination. Serum antibody production was measured by hemagglutination inhibition assay, and antibody titers to individual vaccine viral strains between HF and HC were compared following the influenza season to measure persistence of antibody response. All participants demonstrated early antibody seroprotection (titers 40 hemmaglutination inhibition units [HAU] to 1 strain). While antibody titers waned over time in both groups, titers to A/H3N2 and A/H1N1 strains decreased more in HF participants compared to HC (p=0.004 and p=0.04, respectively). Titers to the B-type strain decreased to below seroprotective levels in both groups.
CONCLUSIONS:

Antibody titers to influenza A vaccine strains wane to below seroprotective levels in HF patients compared to HC, despite similar rates of initial seroprotection and seroconversion. These findings suggest that HF patients may remain at increased risk for influenza infection despite annual vaccination.

Copyright ? 2013 Elsevier Inc. All rights reserved.
KEYWORDS:

Influenza, antibodies INTRODUCTION, vaccine

PMID:
24361852
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/24361852
 
Back
Top Bottom